Back

Pros and cons of human iPSC cardiomyocytes in drug testing and disease modelling: insights from computational modelling

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - 43rd EWGCCE Meeting Cardiac Diseases EHRA Premium Access EHRA 2019

About the speaker

Photo
Doctor Jussi Tapani Koivumaeki

Tampere University, Tampere (Finland)

17 More presentations in this session

Presentation thumbnail
The hidden electrophysiological cardiotoxic effects of rofecoxib are prevented by ischaemic preconditioning
Doctor Z. Husti (Szeged, HU)
Abstract
Presentation thumbnail
A high-throughput system to reliably characterize normal human ventricular electrophysiology from living patients
Doctor A. Olivan-Viguera (Zaragoza, ES)
Abstract
Presentation thumbnail
Advanced morpho-functional analysis on ventricular and atrial tissue reveals sarcomere energetic impairment in hcm patients
Miss E. Lazzeri (Florence, IT)
Abstract
Presentation thumbnail
Istaroxime improves diabetic diastolic dysfunction through SERCA stimulation
Presentation thumbnail
Mechanism of sinus node dysfunction in carriers of the E161K mutation in the SCN5A gene
Assistant Professor R. Wilders (Amsterdam, NL)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - 43rd EWGCCE Meeting

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Sudden cardiac death and autopsy in the era of molecular medicine
thumbnail
Congress Session
When time is the issue
thumbnail
ESC TV Today
Episode 15: Colchicine for secondary prevention - An algorithmic approach to the workup of syncope

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources